Abstract | PURPOSE: METHODS: A systematic literature search using PubMed from January 01, 2009 through January 06, 2015 with a restriction to papers in English was conducted. RESULTS: There were three phase III randomized trials in patients undergoing high-dose chemotherapy and stem cell transplant and eight single arm non-randomized clinical studies (single in patients undergoing transplantation and one in patients receiving multiple-day chemotherapy treatment). We used a total of two randomized clinical trials in this guideline update. For patients receiving treatment for breakthrough chemotherapy-induced nausea and vomiting, a phase III randomized trial investigating the use of olanzapine versus metoclopramide in patients receiving highly emetogenic chemotherapy and a second single arm study looking at the effectiveness of olanzapine were identified. CONCLUSIONS:
|
Authors | Lawrence H Einhorn, Bernardo Rapoport, Rudolph M Navari, Jørn Herrstedt, Mary J Brames |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 25
Issue 1
Pg. 303-308
(01 2017)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 27815710
(Publication Type: Journal Article)
|
Chemical References |
- Antiemetics
- Antineoplastic Agents
|
Topics |
- Antiemetics
(therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Consensus
- Dose-Response Relationship, Drug
- Humans
- Induction Chemotherapy
(adverse effects, methods)
- Nausea
(chemically induced, prevention & control)
- Practice Guidelines as Topic
- Vomiting
(chemically induced, prevention & control)
|